Natco Pharma Share Price: After the weak results of the third quarter of the current financial year, the share price of NatCO Pharma fell by 10 percent on Friday. The company’s shares fell by 20 percent on Thursday a day earlier. The stock was trading at Rs 875.50 per share at around 10:40 am on Friday after reporting a decline of 37.75 percent in the company’s consolidated net profit in the December quarter. A day before this, the stock fell 19.99 percent to close at Rs 973.40 on Thursday 13 February. It reached the lower circuit limit of Rs 973.35 in Intra-Day. It fell 19.99 percent to Rs 975.05 on NSE, which is its lower circuit limit.
On 14 February, the company’s market valuation on NSE was reduced by about Rs 6,000 crore to Rs 15,722.26 crore in two days. In terms of traded volume, the company had a turnover of 44.90 lakh shares on the NSE during the day.
Analysts of the domestic brokerage Dolat Capital said, “NATCO is facing challenges in base business growth besides Revlimid. The growth in all segments is not corresponding to the expectations, which has also led to significant decline in the main margin such as Revolution. “
Hindalco Share Price can climb up to 30% from the current level, Brokerage firm excited by strong results in Q3
“Sales growth of FY26 will depend on the decline in Revlimid Price. The company is expected to have a significant decline in the FY27 results. This is because of this that the competition of the revolution has increased after the patent expiry.”
On February 12, Natco Pharma recorded a profit of Rs 132.4 crore in consolidated net profit in the December quarter to Rs 132.4 crore. The company’s profits were affected due to a decline in formulation exports. NATCO Pharma said in a regulatory filing that the company had earned a consolidated net profit of Rs 212.7 crore in the December quarter of the last financial year.
Disclaimer: (Information provided here is being given only for information. It is necessary to mention here that the investment in the market is subject to risks. Always consult expert before investing as an investor. It is never advised to apply here.)